Kemeny, M. Margaret
Zhao, Fengmin
Forastiere, Arlene A.
Catalano, Paul
Hamilton, Stanley R.
Miedema, Brent W.
Dawson, Nancy A.
Weiner, Louis M.
Smith, Brian D.
Mason, Bernard A.
Graziano, Stephen L.
Gilman, Paul B.
Venook, Alan P.
Pinto, Harlan A.
Whitehead, Robert P.
O’Dwyer, Peter J.
Benson, Al B.
Article History
Received: 24 November 2021
Accepted: 4 October 2022
First Online: 28 October 2022
Disclosures
: Louis Weiner: Celldex Therapeutics, 53 Frontage Road, Suite #220 Hampton, NJ 08827: Scientific Advisory Board (personal fees); CytomX Therapeutics, Inc., 151 Oyster Point Blvd, Suite#400 South San Francisco, CA 94080-1913: External Advisory Board (stock options); Jounce Therapeutics, 1030 Mass Ave, 4th Floor Cambridge, MA 02138: Scientific Advisory Board, Co-Founder (personal fees); Targeted Diagnostic and Therapeutics, Inc., 1045 Andrew Dr #A, West Chester, PA 19380: Investment (stock options); Immunome, Inc, 665 Stockton Drive, Suite 300 Exton, PA 19341: Scientific Advisory Board (stock options); Tessa Therapeutics, 8 Temasek Boulevard, #24-02 Suntec Tower 3, Singapore 038988: Scientific Advisory Board (personal fees); Bioxcel Therapeutics, Inc., 780 E. Main Street Branford, CT 06405: Clinical Advisory Board (grants/research support); Samyang Biopharm USA Inc., One Kendall Square, Bldg 200 Cambridge, MA 02139: Scientific Advisory Board (personal fees). Patents & Copyrights: PCT/US2018/022617.